论文部分内容阅读
[目的]探讨常见肿瘤患者的HBV感染现状。[方法]回顾性研究分析2007年1月～2007年12月中国医学科学院肿瘤医院10724例肿瘤患者及4208例健康体检者和469例该院职工的血清HBsAg阳性率,并与全国普通人群比较。总体与样本率的比较采用Z检验;样本间率的比较采用χ2检验。[结果]所有肿瘤患者血清HBsAg阳性率为8.98%(963/10724),与全国水平(8.57%)相比,差异无统计学意义(Z=1.04,P=0.298);肝肿瘤和淋巴瘤患者的HBsAg阳性率分别为61.19%(443/724)和13.64%(15/110),与健康对照组4.38%(205/4677)相比,差异均有统计学意义(χ2分别为1916.05和20.987,P均为0.000),其优势比(OR)分别为34.39(95%CI:28.022～42.207)和3.444(95%CI:1.963～6.044)。消化道肿瘤组、肺肿瘤组、女性肿瘤组、泌尿肿瘤组、头颈肿瘤组和其他肿瘤组的HBsAg阳性率分别为5.18%、5.61%、4.30%、4.99%、5.63%和5.30%,与健康对照组之间的差异均无统计学意义。[结论]肝肿瘤患者和淋巴瘤患者的HBV感染率较高;HBV感染是原发性肝肿瘤的主要致病因素;HBV感染可能与淋巴瘤的发病相关。
[Objective] To investigate the status of HBV infection in common cancer patients. [Methods] A retrospective study was conducted to analyze the positive rate of HBsAg in 10724 cancer patients, 4208 healthy subjects and 469 patients in Cancer Hospital of Chinese Academy of Medical Sciences from January 2007 to December 2007 and compared with the national general population. The overall comparison with the sample rate using the Z test; sample rate comparison using χ2 test. [Results] The positive rate of HBsAg in all cancer patients was 8.98% (963/10724), which was not significantly different from the national level (8.57%) (Z = 1.04, P = 0.298) HBsAg positive rates were 61.19% (443/724) and 13.64% (15/110), respectively, which were significantly different from those of healthy controls (4.38%, 205/4677) (χ2 = 1916.05 and 20.987, P = 0.000). The odds ratios were 34.39 (95% CI: 28.022-42.207) and 3.444 (95% CI: 1.963-6.044), respectively. The positive rate of HBsAg in gastrointestinal tumor group, lung tumor group, female tumor group, urological tumor group, head and neck tumor group and other tumor groups were 5.18%, 5.61%, 4.30%, 4.99%, 5.63% and 5.30% There was no significant difference between control groups. [Conclusion] The prevalence of HBV infection in patients with liver cancer and lymphoma is high. HBV infection is the main causative factor in primary liver cancer. HBV infection may be related to the onset of lymphoma.